Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands [1]

Leukemia

Volumn 18, Issue 12, 2004, Pages 2032-2035

  de Bont, J M ^a   van der Holt, B ^b   Dekker, A W ^c   van der Does van den Berg, A ^d   Sonneveld, R ^b   Pieters, Rob ^a,d  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d DCOG   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC ANTIMETABOLITE; ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CHILD CARE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RESISTANCE; DRUG TOXICITY; HUMAN; LETTER; MORTALITY; NETHERLANDS; ONSET AGE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT REFERRAL; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; SIDE EFFECT;

EID: 11144266589     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403538     Document Type: Letter

References (9)

1. Boissel N, Auclerc MF, Lheritier V, Perel Y, Thomas X, Leblanc T et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21: 774-780.
2. Abromowitch M, Ochs J, Pui CH, Kalwinsky D, Rivera GK, Fairclough D et al. High-dose methotrexate improves clinical outcome in children with acute lymphoblastic leukemia: St Jude Total Therapy Study X. Med Pediatr Oncol 1988; 16: 297-303.
3. Richards S, Gray R, Peto R, Gaynon P, Masera G. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet 1996; 347: 1783-1788.
4. Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000; 18: 1508-1516.
5. Dibenedetto SP, Guardabasso V, Ragusa R, Di Cataldo A, Miraglia V, D'Amico S et al. 6-Mercaptopurine cumulative dose: a critical factor of maintenance therapy in average risk childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 1994; 11: 251-258.
6. Arico M, Valsecchi MG, Camitta B. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
7. Weisdorf DJ, Billett AL, Hannan P, Ritz J, Sallan SE, Steinbuch M et al. Autologous vs unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood 1997; 90: 2962-2968.
8. Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K et al. Dexamethasone vs prednisone and daily oral vs weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101: 3809-3817.
9. Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97: 1211-1218.